Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Primary cervical screening with high risk human papillomavirus testing: observational study.

Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, Smith J, Evans C, Giles T, Frew V, Tyler X, Sargent A, Parker J, Holbrook M, Hunt K, Tidbury P, Levine T, Smith D, Patnick J, Stubbs R, Moss S, Kitchener H.

BMJ. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240.

2.

PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase 3 trial.

Kitson S, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton P, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ.

Clin Cancer Res. 2018 Dec 18. pii: clincanres.3339.2018. doi: 10.1158/1078-0432.CCR-18-3339. [Epub ahead of print]

PMID:
30563932
3.

The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.

MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M, Higgins CL, Kamieniorz M, Pemberton PW, Kirmani BH, Ahmed B, Syed AA, Ammori BJ, Renehan AG, Kitchener HC, Crosbie EJ.

Int J Cancer. 2019 Feb 1;144(3):641-650. doi: 10.1002/ijc.31913. Epub 2018 Nov 20.

PMID:
30289975
4.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
5.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

6.

To promote maintenance or treatment, is that the question?

Bookman MA, Kitchener HC.

Lancet Oncol. 2017 Sep;18(9):1151-1152. doi: 10.1016/S1470-2045(17)30567-3. Epub 2017 Jul 25. No abstract available.

PMID:
28754484
7.

Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).

Tsiachristas A, Gittins M, Kitchener H, Gray A.

J Med Screen. 2018 Jun;25(2):99-109. doi: 10.1177/0969141317704679. Epub 2017 May 22.

8.

Cervical cancer: A global health crisis.

Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK.

Cancer. 2017 Jul 1;123(13):2404-2412. doi: 10.1002/cncr.30667. Epub 2017 May 2. Review.

9.

The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.

Stuart GCE, Kitchener HC, Vermorken JB, Quinn MJ, Small W Jr, Pujade-Lauraine E, Chou H, Wong M, Bacon M.

Int J Gynecol Cancer. 2017 May;27(4):813-818. doi: 10.1097/IGC.0000000000000934.

PMID:
28441253
10.

Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen.

Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC, Townsend PA.

Cancer Med. 2017 Feb;6(2):408-415. doi: 10.1002/cam4.967. Epub 2017 Jan 21.

11.

Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme.

McBride E, Marlow L, Forster AS, Moss S, Myles J, Kitchener H, Patnick J, Waller J.

BMJ Open. 2016 Dec 23;6(12):e014356. doi: 10.1136/bmjopen-2016-014356.

12.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, Renehan AG, Kitchener HC, Edmondson RJ, Crosbie EJ.

Mod Pathol. 2017 Mar;30(3):459-468. doi: 10.1038/modpathol.2016.203. Epub 2016 Dec 2.

13.

Cervix Cancer Research Network (CCRN): Improving Access to Cervix Cancer Trials on a Global Scale.

Gaffney D, Small B, Kitchener H, Young Ryu S, Viswanathan A, Trimble T, Covens A, Wilailak S, Lertkhachonsuk AA, Sitathanee C, Mahantshetty U, Fisher B, Springer S, Pollatz T, Spiller A, Bacon M, Jhingran A.

Int J Gynecol Cancer. 2016 Nov;26(9):1690-1693.

PMID:
27779548
14.

Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.

Wan YL, Beverley-Stevenson R, Carlisle D, Clarke S, Edmondson RJ, Glover S, Holland J, Hughes C, Kitchener HC, Kitson S, Miles T, Morley R, Morrison J, Nelson L, Powell M, Sadler L, Tomlinson A, Tylko-Hill K, Whitcombe J, Crosbie EJ.

Gynecol Oncol. 2016 Nov;143(2):287-293. doi: 10.1016/j.ygyno.2016.08.333. Epub 2016 Sep 1.

15.

A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC).

Kitchener HC, Gittins M, Rivero-Arias O, Tsiachristas A, Cruickshank M, Gray A, Brabin L, Torgerson D, Crosbie EJ, Sargent A, Roberts C.

Health Technol Assess. 2016 Sep;20(68):1-138. doi: 10.3310/hta20680.

16.

Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.

Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K.

Int J Cancer. 2016 Dec 15;139(12):2771-2780. doi: 10.1002/ijc.30392.

17.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

18.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group.

Lancet Infect Dis. 2016 Oct;16(10):1154-1168. doi: 10.1016/S1473-3099(16)30120-7. Epub 2016 Jun 28.

PMID:
27373900
19.

A prospective study of anal cancer screening in HIV-positive and negative MSM.

Schofield AM, Sadler L, Nelson L, Gittins M, Desai M, Sargent A, McMahon RF, Hill J, Crosbie EJ, Patnick J, Kitchener HC.

AIDS. 2016 Jun 1;30(9):1375-83. doi: 10.1097/QAD.0000000000001045.

PMID:
26836788
20.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC.

Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. Review.

PMID:
26676202
21.

Premalignant disease in the genital tract in pregnancy.

Owens GL, Kitchener HC.

Best Pract Res Clin Obstet Gynaecol. 2016 May;33:33-43. doi: 10.1016/j.bpobgyn.2015.10.009. Epub 2015 Oct 19.

PMID:
26597347
22.

Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.

Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum NR, Lecuru F, Small W Jr; Gynecologic Cancer InterGroup Cervix Cancer brainstorming day.

Int J Gynecol Cancer. 2016 Jan;26(1):199-207. doi: 10.1097/IGC.0000000000000587.

23.

HPV testing alone is not as safe as cytology and selective HPV testing: AGAINST: There is powerful evidence for primary cervical screening.

Kitchener H.

BJOG. 2016 Jan;123(1):68. doi: 10.1111/1471-0528.13638. Epub 2015 Nov 3. No abstract available.

24.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM.

J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.

PMID:
26417001
25.

The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.

Crosbie EJ, Bailey A, Sargent A, Gilham C, Peto J, Kitchener HC.

J Clin Microbiol. 2015 Nov;53(11):3553-9. doi: 10.1128/JCM.01578-15. Epub 2015 Sep 2.

26.

A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.

Sivalingam V, McVey R, Gilmour K, Ali S, Roberts C, Renehan A, Kitchener H, Crosbie E.

Lancet. 2015 Feb 26;385 Suppl 1:S90. doi: 10.1016/S0140-6736(15)60405-6.

PMID:
26312913
27.

The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.

Gaffney DK, Suneja G, Ryu SY, McCormick M, Plante M, Mileshkin L, Small W Jr, Bacon M, Stuart G, Kitchener H.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):506-8. doi: 10.1016/j.ijrobp.2015.02.054. No abstract available.

28.

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM.

Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.

PMID:
26002111
29.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

30.

A study of cellular counting to determine minimum thresholds for adequacy for liquid-based cervical cytology using a survey and counting protocol.

Kitchener HC, Gittins M, Desai M, Smith JH, Cook G, Roberts C, Turnbull L.

Health Technol Assess. 2015 Mar;19(22):i-xix, 1-64. doi: 10.3310/hta19220.

31.

The cervix cancer research network: increasing access to cancer clinical trials in low- and middle-income countries.

Suneja G, Bacon M, Small W Jr, Ryu SY, Kitchener HC, Gaffney DK.

Front Oncol. 2015 Feb 19;5:14. doi: 10.3389/fonc.2015.00014. eCollection 2015.

32.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL.

Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.

33.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

34.

Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study.

Flatley JE, Sargent A, Kitchener HC, Russell JM, Powers HJ.

BMC Cancer. 2014 Nov 3;14:803. doi: 10.1186/1471-2407-14-803.

35.

Urine testing for HPV.

Kitchener HC, Owens GL.

BMJ. 2014 Sep 16;349:g5542. doi: 10.1136/bmj.g5542. No abstract available.

PMID:
25230583
36.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; VIVIANE Study Group.

Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1.

PMID:
25189358
37.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

38.

Ovarian cancer.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA.

Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21. Review.

PMID:
24767708
39.

HPV-based screening for prevention of invasive cervical cancer - Authors' reply.

Ronco G, Meijer CJ, Segnan N, Kitchener H, Giorgi-Rossi P, Peto J, Dillner J.

Lancet. 2014 Apr 12;383(9925):1295. doi: 10.1016/S0140-6736(14)60645-0. No abstract available.

PMID:
24725577
40.

Interventions to improve cervical cancer screening uptake amongst young women: a systematic review.

Albrow R, Blomberg K, Kitchener H, Brabin L, Patnick J, Tishelman C, Törnberg S, Sparén P, Widmark C.

Acta Oncol. 2014 Apr;53(4):445-51. doi: 10.3109/0284186X.2013.869618. Epub 2014 Feb 7. Review.

PMID:
24660768
41.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8.

42.

Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.

Cuschieri K, Cubie H, Graham C, Rowan J, Hardie A, Horne A, Earle CB, Bailey A, Crosbie EJ, Kitchener H.

J Clin Virol. 2014 Feb;59(2):104-8. doi: 10.1016/j.jcv.2013.12.001. Epub 2013 Dec 12.

PMID:
24380720
43.

Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.

Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting.

Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb.

PMID:
24257568
44.

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ; International HPV screening working group.

Lancet. 2014 Feb 8;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3. Erratum in: Lancet. 2015 Oct 10;386(10002):1446.

PMID:
24192252
45.

Developing role of HPV in cervical cancer prevention.

Kitchener HC, Denton K, Soldan K, Crosbie EJ.

BMJ. 2013 Aug 7;347:f4781. doi: 10.1136/bmj.f4781. Review. No abstract available. Erratum in: BMJ. 2013;347:f5207.

PMID:
23926316
46.

Human papillomavirus and cervical cancer.

Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC.

Lancet. 2013 Sep 7;382(9895):889-99. doi: 10.1016/S0140-6736(13)60022-7. Epub 2013 Apr 23.

PMID:
23618600
47.

Therapy of human papillomavirus-related disease.

Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein MH.

Vaccine. 2012 Nov 20;30 Suppl 5:F71-82. doi: 10.1016/j.vaccine.2012.05.091. Review.

48.

Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study.

Legood R, Smith M, Lew JB, Walker R, Moss S, Kitchener H, Patnick J, Canfell K.

BMJ. 2012 Oct 31;345:e7086. doi: 10.1136/bmj.e7086.

49.

Development of a pre-notification leaflet to encourage uptake of cervical screening at first invitation: a qualitative study.

Sadler L, Albrow R, Shelton R, Kitchener H, Brabin L.

Health Educ Res. 2013 Oct;28(5):793-802. doi: 10.1093/her/cys103. Epub 2012 Oct 30.

PMID:
23111151
50.

Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis.

Kong A, Johnson N, Kitchener HC, Lawrie TA.

J Natl Cancer Inst. 2012 Nov 7;104(21):1625-34. doi: 10.1093/jnci/djs374. Epub 2012 Sep 6. Review.

PMID:
22962693

Supplemental Content

Loading ...
Support Center